Literature DB >> 25356525

Clinical and genetic investigation of 17 Japanese patients with hyperekplexia.

Jun Mine1, Takeshi Taketani, Kazushi Yoshida, Fusako Yokochi, Junpei Kobayashi, Koichi Maruyama, Etsuro Nanishi, Mayumi Ono, Atsushi Yokoyama, Hidee Arai, Shiho Tamaura, Yasuhiro Suzuki, Shusuke Otsubo, Takashi Hayashi, Masahiko Kimura, Kazuko Kishi, Seiji Yamaguchi.   

Abstract

AIM: The aim of the study was to determine clinical and genetic characteristics of Japanese patients with hyperekplexia.
METHOD: Clinical courses, responses to antiepileptic drugs, outcomes, and genetic testing were investigated in 17 Japanese patients (nine males, eight females, median age 1y, range birth-45y) with hyperekplexia.
RESULTS: In all patients, muscle stiffness and startle responses appeared soon after birth. Only seven patients were diagnosed with hyperekplexia before 1 year of age. Seven patients had been misdiagnosed with other disorders such as epilepsy and adult-onset anxiety neurosis. Umbilical/inguinal hernias were seen in 10 patients. Life-threatening events were noted in four patients. Clonazepam was the most effective drug. Muscle stiffness completely disappeared in 12 patients before 5 years of age, whereas startle responses resolved in only three patients. Mutations in the GLRA1 and GLRB genes were identified in 16 patients and one patient respectively. In 14 patients, the mutation showed autosomal dominant inheritance; in the other three, inheritance was autosomal recessive. p.R271Q of GLRA1 was the most frequent mutation, found in 10 patients. Novel mutations, p.A272P and p.A384P of GLRA1, were detected. Clinical severity and outcome varied even in the same family.
INTERPRETATION: Early correct diagnosis is essential for prevention of accidental injuries and to provide appropriate treatments for hyperekplexia. Clonazepam is effective, although the time taken for startle responses to resolve varied.
© 2014 Mac Keith Press.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25356525     DOI: 10.1111/dmcn.12617

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  7 in total

1.  A novel nonsense autosomal dominant mutation in the GLRA1 gene causing hyperekplexia.

Authors:  Ivan Milenkovic; Alexander Zimprich; Martin Gencik; Kirsten Platho-Elwischger; Stefan Seidel
Journal:  J Neural Transm (Vienna)       Date:  2018-09-04       Impact factor: 3.575

2.  A Missense Mutation A384P Associated with Human Hyperekplexia Reveals a Desensitization Site of Glycine Receptors.

Authors:  Chen-Hung Wang; Ciria C Hernandez; Junyi Wu; Ning Zhou; Hsin-Yu Hsu; Mei-Lin Shen; Yi-Ching Wang; Robert L Macdonald; Dong Chuan Wu
Journal:  J Neurosci       Date:  2018-02-13       Impact factor: 6.167

3.  The synthetic cannabinoid dehydroxylcannabidiol restores the function of a major GABAA receptor isoform in a cell model of hyperekplexia.

Authors:  Guichang Zou; Jing Xia; Qianqian Han; Dan Liu; Wei Xiong
Journal:  J Biol Chem       Date:  2019-11-22       Impact factor: 5.157

4.  Excessive Startle with Novel GLRA1 Mutations in 4 Chinese Patients and a Literature Review of GLRA1-Related Hyperekplexia.

Authors:  Feixia Zhan; Chao Zhang; Shige Wang; Zeyu Zhu; Guang Chen; Mingliang Zhao; Li Cao
Journal:  J Clin Neurol       Date:  2020-04       Impact factor: 3.077

5.  Novel mutations in SLC6A5 with benign course in hyperekplexia.

Authors:  Hormos Salimi Dafsari; Amit Kawalia; Rosanne Sprute; Mert Karakaya; Anna Malenica; Peter Herkenrath; Peter Nürnberg; Susanne Motameny; Holger Thiele; Sebahattin Cirak
Journal:  Cold Spring Harb Mol Case Stud       Date:  2019-12-13

Review 6.  Research Progress in the Study of Startle Reflex to Disease States.

Authors:  Junfeng Zhang; Meng Wang; Baoyu Wei; Jiangwei Shi; Tao Yu
Journal:  Neuropsychiatr Dis Treat       Date:  2022-02-24       Impact factor: 2.570

Review 7.  Impaired Glycine Receptor Trafficking in Neurological Diseases.

Authors:  Natascha Schaefer; Vera Roemer; Dieter Janzen; Carmen Villmann
Journal:  Front Mol Neurosci       Date:  2018-08-21       Impact factor: 5.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.